Paper24979481
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F and 7 others. Cochrane Database Syst Rev, 2014. Cited by 42 papers, by iCite.
Cite this record
ConductScience Library. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Papers, record 24979481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24979481
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Androgen Antagonists | Major topic |
| Antineoplastic Agents, Hormonal | Major topic |
| Gonadotropin-Releasing Hormone | Major topic |
| Orchiectomy | Major topic |
| Prostatic Neoplasms | Major topic |
| Anilides | |
| Disease Progression | |
| Flutamide | |
| Goserelin | |
| Humans | |
| Leuprolide | |
| Male | |
| Nitriles | |
| Randomized Controlled Trials as Topic | |
| Tosyl Compounds | |
| Triptorelin Pamoate | |
| Drug Monitoring |
Source PubMed
References160
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22562608 | Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. | Eur J Clin Pharmacol | 2012 | https://conductscience.org/library/papers/22562608 | PubMed |
| 2 | 17102802 | Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. | Prostate Cancer Prostatic Dis | 2007 | https://conductscience.org/library/papers/17102802 | PubMed |
| 3 | 16822873 | Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. | J Clin Pathol | 2007 | https://conductscience.org/library/papers/16822873 | PubMed |
| 4 | 12111919 | Quantifying heterogeneity in a meta-analysis. | Stat Med | 2002 | https://conductscience.org/library/papers/12111919 | PubMed |
| 5 | 17692108 | Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer. | Clin Endocrinol (Oxf) | 2008 | https://conductscience.org/library/papers/17692108 | PubMed |
| 6 | 8973848 | Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. | Clin Oncol (R Coll Radiol) | 1996 | https://conductscience.org/library/papers/8973848 | PubMed |
| 7 | 17991545 | Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. | Urology | 2007 | https://conductscience.org/library/papers/17991545 | PubMed |
| 8 | 22147380 | Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. | JAMA | 2011 | https://conductscience.org/library/papers/22147380 | PubMed |
| 9 | 22498209 | Conflict of interest in urology. | J Urol | 2012 | https://conductscience.org/library/papers/22498209 | PubMed |
| 10 | 9471040 | Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. | Eur Urol | 1998 | https://conductscience.org/library/papers/9471040 | PubMed |
| 11 | 9510340 | Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. | Urology | 1998 | https://conductscience.org/library/papers/9510340 | PubMed |
| 12 | 16430622 | Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. | BJU Int | 2006 | https://conductscience.org/library/papers/16430622 | PubMed |
| 13 | 17332110 | Conflict of interest in orthopaedic research. An association between findings and funding in scientific presentations. | J Bone Joint Surg Am | 2007 | https://conductscience.org/library/papers/17332110 | PubMed |
| 14 | 3798631 | Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. | Urology | 1987 | https://conductscience.org/library/papers/3798631 | PubMed |
| 15 | 11489683 | Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. | Urology | 2001 | https://conductscience.org/library/papers/11489683 | PubMed |
| 16 | 15540740 | Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. | J Urol | 2004 | https://conductscience.org/library/papers/15540740 | PubMed |
| 17 | 16858161 | Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. | Am J Ther | 2006 | https://conductscience.org/library/papers/16858161 | PubMed |
| 18 | 11098244 | Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. | Evid Rep Technol Assess (Summ) | 1999 | https://conductscience.org/library/papers/11098244 | PubMed |
| 19 | 8708714 | Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. | J Clin Oncol | 1996 | https://conductscience.org/library/papers/8708714 | PubMed |
| 20 | 11905923 | Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. | J Urol | 2002 | https://conductscience.org/library/papers/11905923 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39154013 | Telomerase related molecular subtype and risk model reveal immune activity and evaluate prognosis and immunotherapy response in prostate cancer. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/39154013 | PubMed |
| 39062524 | Design, Synthesis, Characterization, and Cytotoxicity of New Pyrazolylmethylene-2-thioxoimidazolidin-4-one Derivatives towards Androgen-Sensitive LNCaP Prostate Cancer Cells. | Biomolecules | 2024 | https://conductscience.org/library/papers/39062524 | PubMed |
| 38298446 | Long-term disease stability with bicalutamide in a man with aggressive angiomyxoma: case report and state of art. | Front Oncol | 2023 | https://conductscience.org/library/papers/38298446 | PubMed |
| 37092584 | Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8+ T lymphocytes, NK-cells, and high frequency of CD73+ stromal cells. | Cancer Rep (Hoboken) | 2023 | https://conductscience.org/library/papers/37092584 | PubMed |
| 35582006 | Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators. | Cancer Drug Resist | 2021 | https://conductscience.org/library/papers/35582006 | PubMed |
| 35118979 | Misconduct in research integrity: Assessment the quality of systematic reviews in Cochrane urological cancer review group. | Turk J Urol | 2021 | https://conductscience.org/library/papers/35118979 | PubMed |
| 35017008 | Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial. | Int J Radiat Oncol Biol Phys | 2022 | https://conductscience.org/library/papers/35017008 | PubMed |
| 34692585 | Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study. | Prostate Int | 2021 | https://conductscience.org/library/papers/34692585 | PubMed |
| 34350976 | Degarelix for treating advanced hormone-sensitive prostate cancer. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/34350976 | PubMed |
| 31746656 | Surgical versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. | J Urol | 2020 | https://conductscience.org/library/papers/31746656 | PubMed |
| 31194882 | Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. | Cochrane Database Syst Rev | 2019 | https://conductscience.org/library/papers/31194882 | PubMed |
| 30830274 | Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review. | World J Urol | 2020 | https://conductscience.org/library/papers/30830274 | PubMed |
| 30648519 | Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis. | Curr Clin Pharmacol | 2019 | https://conductscience.org/library/papers/30648519 | PubMed |
| 30637900 | Androgen deprivation therapy for prostate cancer and risk of dementia. | BJU Int | 2019 | https://conductscience.org/library/papers/30637900 | PubMed |
| 27586377 | Treatment of Metastatic Prostate Cancer in Older Adults. | Curr Oncol Rep | 2016 | https://conductscience.org/library/papers/27586377 | PubMed |
| 27390687 | Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis. | Med J Islam Repub Iran | 2016 | https://conductscience.org/library/papers/27390687 | PubMed |
| 27330919 | The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis. | Springerplus | 2016 | https://conductscience.org/library/papers/27330919 | PubMed |
| 27246172 | An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. | Adv Ther | 2016 | https://conductscience.org/library/papers/27246172 | PubMed |
| 27245503 | Prostate cancer: Combining endocrine treatment and radiotherapy: a bright future. | Nat Rev Urol | 2016 | https://conductscience.org/library/papers/27245503 | PubMed |
| 27222641 | Penile Rehabilitation Strategies Among Prostate Cancer Survivors. | Rev Urol | 2015 | https://conductscience.org/library/papers/27222641 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24979481
GET https://conductscience.org/api/papers/v1/24979481/references?page=2